论文部分内容阅读
自60年代口服避孕药(OC)首次应用以来,全世界使用妇女已达5千多万。在这期间,甾体OC的剂量及其用药量的时间计划已有了变化,原来的固定剂量复合制剂先发展为序贯用药最近已为多时相给药。每一步发展都使OC更接近理想达到可靠的避孕作用和最低的代谢影响及全身副作用。在世界范围临床研究中,多相OC制剂的安全性和有效性已得到证实。多相制剂设计的演变过程随着人们对雌、孕激素作用的进一步了解,对OC组成成分的比例使之向符合正常月经周期激素类型生理变化,也就是要使雌、孕激素剂量的变化与正常月经周期激素产生的峰值相一致。然而,因OC含性甾体激素,是具有一定生物学作用的药理
Since the first use of oral contraceptives (OCs) in the 1960s, more than 50 million women have been used worldwide. During this period, the timing of the dose of steroid OC and its dosage has changed, and the original fixed-dose combination first developed to sequential administration has recently been multi-phase administered. Each step of development brings OC closer to the ideal to achieve reliable contraception and minimal metabolic effects as well as systemic side effects. The safety and efficacy of multi-phase OC formulations have been demonstrated in worldwide clinical studies. The evolution of multiphase formulation design As people learn more about the effects of estrogen and progestin, the proportion of OC constituents makes them physiologically relevant to the normal menstrual cycle hormone type, that is, The peak of the normal menstrual cycle hormone production is consistent. However, due to OC-containing steroid hormone, is a certain biological role of pharmacology